Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-232 Clinical Pharmacology Study in Healthy Adult Males
jRCT2080225220Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of K-232 in ocular hypertension (3 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Plasma pharmacokinetics of ripasudil, M1 metabolite, and brimonidine and Change in intraocular pressure (IOP). Started Jun 2020; status: completed.
02
Drugs
K-232
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on jRCT2080225220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225220.